Editas received a payment after reaching clinical development milestones in its collaboration with Bristol Myers Squibb. The payment adds partnership revenue, though the report gives no amount.
The payment adds revenue from a research partnership and shows that clinical development milestones were reached. The report gives no amount, so its size and importance to Editas's overall finances cannot be measured.
Bristol Myers Squibb triggered a payment to Editas under their existing collaboration after clinical milestones were reached. The report gives no payment amount or business effect for Bristol Myers Squibb.
Follow Editas Medicine (EDIT) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for EDIT